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Abstract
Chronic pruritus is an emerging health problem with a significant impact on quality of life. Recent
advances in our understanding of newly discovered pathways and receptors for itch have been made.
It is hoped that recent advancements will also drive the development of novel therapies for this often-
neglected and bothersome symptom.
Introduction and context
Pruritus is a common symptom that has multifactorial
etiologies that range from skin to neural and systemic
diseases, and its pathophysiology has been, until
recently, poorly understood. Epidemiological studies
have shown that it is common in 8-12% of the general
population [1]. Chronic pruritus has a profound impact
on quality of life by disturbing sleep and affecting
attention. A large study has shown that hemodialysis
patients who itch have a higher mortality risk, which is
related to their lack of sleep [2].
Recent advances
A specific separate pathway for histamine-induced itch
was found more than a decade ago in a subset of C nerve
fibers in humans and later in spinal projection neurons of
cats [3,4]. In 2007, investigators discovered a separate
parallel itch processing pathway activated by cowhage
spicules(Mucunapruriens),whichrevealedanactivationof
peripheral nerve fibersin humansas wellas specificspinal
projection neurons in primates [5-7]. However, these C
fiber afferents are not itch-specific since they are also
activatedbyheatstimuli that inducethe sensationofpain.
Cowhage is also known to induce a burning sensation
along withitch.The active ingredient incowhage has been
isolated as a cysteine protease (mucunanin) that activates
proteinase-activated receptor 2 (PAR2) and PAR4 [8] in
nerve fibers and keratinocytes. PAR2 receptors and their
ligands, serine proteases, have previously been demon-
strated to have a significant role in the itch associated with
atopic eczema [9]. Recently, cathepsin S, an endogenous
cysteine protease secreted by keratinocytes, was found to
induce itch [10]. This finding suggests that cathepsin S
may have a role as an itch mediator in inflammatory skin
diseases.
New evidence for a specific pathway for itch was
generated by the findings of neurons expressing a
gastrin-releasing peptide receptor (GRPR) gene that
transmit only itch and not pain [11]. GRPR is a G
protein-coupled receptor for gastrin-releasing peptide
(GRP), a bombesin-like peptide that is widely distrib-
uted in the gastrointestinal tract and central nervous
system. Moreover, in a model of chronic itch and atopic
dermatitis-like skin lesions in mice, the mice pretreated
with a GRPR antagonist presented no scratching [12].
The role of this receptor in humans and in atopic eczema
remains to be defined.
The common view is that the epidermis may act as a
receptor for itch, but a specific receptor has not yet been
clearly identified. Recent studies provide evidence that,
indeed, there are itch-specific receptors in the skin. A
subset of C nerve fibers that contain MRGPRA (Mas-
related G protein-coupled receptor member A), a sub-
family of G protein-coupled receptors, were found to
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Chloroquine is an antimalarial drug that is known to
induce itch in humans, especially in those with dark skin
color (Africans). These neurons did respond to histamine
and capsaicin (these cells had also expressed GRP, the
ligand for GRPR) as well as to histamine, providing
evidencethatthesecellsplayanimportantroleinpruritus.
Another recent discovery of a possible itch receptor in
humanswasfoundinlichenamyloidosis,alocalizedform
of severe itch common in Asians and Hispanics. A
mutation in the oncostatin M receptor (OSMR) gene,
which encodes OSMR-beta, an interleukin-31 (IL-31)
cytokine receptor, was found in these patients [14]. IL-31
(aTh2cell-derivedcytokine)waspreviouslyfoundtoelicit
itch inatopicdermatitisandprurigonodularis[15].AnIL-
31 antibody effectively reduced scratching behavior in an
atopic dermatitis-like murine model, suggesting the
potential therapeutic role of IL-31 antibody in the
treatment of chronic itch [16].
The concept of pruritic mediators that act centrally and
peripherally is becoming more widely recognized. Among
the long list of mediators, opioids have a major role in
generalized pruritus. It has been known for decades that
analgesia obtained with mu opioids induces itch, most
probably via reduction of inhibition of pain fibers,
whereas mu antagonists, such as naltrexone, inhibit itch.
Ithasbeensuggestedthatchronicitchisassociatedwithan
imbalance between mu and kappa opioid systems [17].
This effect is not limited to the central nervous system but
also occurs in the skin as demonstrated in keratinocytes of
patients with atopic eczema [18]. This latter finding led to
thedevelopmentofanovelkappaopioidreceptoragonist.
Recent resultsofa phase III,double-blindstudy in chronic
kidney disease-associated pruritus showed that orally
taken nalfurafine effectively reduced itch [19]. Of note,
nalfurafine was officially approved for clinical use as an
antipruritic for chronic kidney disease-associated pruritus
in Japan last year.
Chronic pruritus shares many similarities, including
peripheral and central sensitization, with chronic pain
[20]. Therefore, many endogenous inflammatory media-
tors that are involved in chronic pain via sensitization of
nociceptive nerve fibers such as prostanoids, serotonin,
nerve growth factor, and transient receptor potential
vanilloids (TRPVs) also have a role in chronic pruritus
[21]. TRPV1 and TRPV3 have recently been implicated in
the pathogenesis of pruritus [22,23]. These observations
taken together may suggest that TRPV1 is a relay through
which capsaicin exerts its antipruritic effect. Beneficial
effects of capsaicin have been reported in chronic,
localized pruritic disorders, particularly those of neuro-
pathic origin. Substance P is a neuropeptide widely
distributed in peripheral nerve fibers and the central
nervous system and is known to intensify itch perception.
A recent study in rats demonstrated that the destruction of
substance P receptor neurokinin 1-expressing neurons in
the spinal dorsal horn significantly attenuated scratching
response [24]. These results suggest that substance P and
its neurokinin receptor 1 have a role as itch transmitters in
the central nervous system [24].
The existence of central nerve sensitization is demon-
strated by studies in chronic itch patients who perceive
painful stimuli as itching [21]. Moreover, robust activa-
tion in the brain in areas involved in central sensitization
has been noted in chronic itch [25]. This explains the
rationale of using neuroleptics and antidepressantsin the
treatment of chronic pruritus [26]. The exact mechan-
isms, as well as the magnitude of their beneficial effects,
remain largely unclear.
Implications for clinical practice
It is time to re-think the current itch treatment strategy
that mainly includes topical corticosteroids and oral
antihistamines that have limited effect in most types of
chronic pruritus. At present, clinical management of
chronic pruritus should include the use of drugs that
reduce neuronal sensitization for pain (such as gaba-
pentin) and pregabalin and selective serotonin and
neuroepinpherine antidepressants, either as monothera-
pies or in combination. Hopefully, in the future, we will
see a wide range of topical and systemic therapies that
target the various receptors and neural pathways that
mediate itch of different types and lead to improved
quality of life for millions of pruritic patients.
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